Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Vinayak Muralidhar, M.D.

Title
Institution
Department
Address

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Lamba N, Butler S, Mahal BA, Trinh QD, Rose B, King M, Orio P, Mouw KW, Martin N, Leeman JE, Feng FY, Nguyen PL, Muralidhar V. Three-tiered sub-classification system of high-risk prostate cancer in men managed with radical prostatectomy: Implications for treatment decision-making. Urology. 2020 Aug 04. PMID: 32763323.
    Citations:    
  2. Dee EC, Nezolosky MD, Chipidza FE, Arega MA, Butler SS, Sha ST, Mahal BA, Nguyen PL, Yang DD, Muralidhar V. Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities. Prostate. 2020 Jul 13. PMID: 32659024.
    Citations:    
  3. Yang DD, Muralidhar V, Mahal BA, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Martin NE, King MT, Mouw KW, Choueiri TK, Trinh QD, Nguyen PL, Orio PF. Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urol Oncol. 2020 Jul 09. PMID: 32654951.
    Citations:    
  4. Muralidhar V, Dee EC, D'Amico AV. Sequencing Treatments for Cancer During the COVID-19 Pandemic. Am J Clin Oncol. 2020 07; 43(7):457-458. PMID: 32467526.
    Citations:    
  5. Tabrizi S, Alshalalfa M, Mahal BA, Davicioni E, Liu Y, Mouw KW, Feng F, Nguyen PL, Muralidhar V. Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. Int J Radiat Oncol Biol Phys. 2020 Jun 22. PMID: 32585335.
    Citations:    
  6. Fefer M, Lamb CC, Shen AH, Clardy P, Muralidhar V, Devlin PM, Dee EC. Multilingual Analysis of the Quality and Readability of Online Health Information on the Adverse Effects of Breast Cancer Treatments. JAMA Surg. 2020 Jun 10. PMID: 32520317.
    Citations:    
  7. Dee EC, Fefer M, Hammoudeh L, Yu Z, Cantalino JM, Johnson TJ, O'Farrell DA, Bui AN, Muralidhar V, Mahal BA, Nguyen PL, LeBoeuf NR, Devlin PM. Surface applicator high-dose-rate fractionated brachytherapy for superficial cancers of the penis: A single-center case series and national database comparison. J Am Acad Dermatol. 2020 Apr 19. PMID: 32320768.
    Citations:    
  8. Menon H, Patel RR, Ludmir EB, Muralidhar V, Cushman TR, Amini A, Seyedin SN, Nguyen PL, Verma V. Local management of preinvasive and clinical T1-3 penile cancer: utilization of diverse treatment modalities. Future Oncol. 2020 May; 16(14):955-960. PMID: 32301342.
    Citations:    
  9. Butler SS, Dee EC, Lamba N, Sha ST, Mahal BA, Whitbeck A, Makkar R, Wangoe J, Mouw KW, Nguyen PL, Muralidhar V. Validation of a subclassification for high-risk prostate cancer in a prospective cohort. Cancer. 2020 May 15; 126(10):2132-2138. PMID: 32073662.
    Citations:    
  10. Sha ST, Perni S, Muralidhar V, Mahal BA, Sanford NN, Nguyen PL, Dee EC. Trends, Quality, and Readability of Online Health Resources on Proton Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 May 01; 107(1):33-38. PMID: 31987973.
    Citations:    
  11. Fullerton ZH, Butler SS, Mahal BA, Muralidhar V, Schoenfeld JD, Tishler RB, Margalit DN. Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status. Cancer. 2020 Apr 01; 126(7):1424-1433. PMID: 31930488.
    Citations:    
  12. Mahal BA, Alshalalfa M, Zhao SG, Beltran H, Chen WS, Chipidza F, Davicioni E, Karnes RJ, Ku SY, Lotan TL, Muralidhar V, Rebbeck TR, Schaeffer EM, Spratt DE, Feng FY, Nguyen PL. Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer. 2020 Apr 01; 126(7):1407-1412. PMID: 31905251.
    Citations:    
  13. Butler SS, Muralidhar V, Zhao SG, Sanford NN, Franco I, Fullerton ZH, Chavez J, D'Amico AV, Feng FY, Rebbeck TR, Nguyen PL, Mahal BA. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer. 2020 02 15; 126(4):717-724. PMID: 31794057.
    Citations:    
  14. Muralidhar V, Mahal BA, Butler S, Lamba N, Yang DD, Leeman J, D'Amico AV, Nguyen PL, Trinh QD, Orio PF, King MT. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. J Urol. 2019 11; 202(5):973-978. PMID: 31144590.
    Citations:    
  15. Butler SS, Loeb S, Cole AP, Zaslowe-Dude C, Muralidhar V, Kim DW, Schaeffer EM, Trinh QD, Nguyen PL, Mahal BA. United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer Prostatic Dis. 2020 03; 23(1):179-183. PMID: 31591454.
    Citations:    
  16. Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF. Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. J Natl Compr Canc Netw. 2019 08 01; 17(8):941-948. PMID: 31390585.
    Citations:    
  17. Muralidhar V, Zhang J, Wang Q, Mahal BA, Butler SS, Spratt DE, Davicioni E, Sartor O, Feng FY, Mouw KW, Nguyen PL. Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019 11 01; 105(3):621-627. PMID: 31271825.
    Citations:    
  18. Mahal AR, Butler S, Franco I, Muralidhar V, Larios D, Pike LRG, Zhao SG, Sanford NN, Dess RT, Feng FY, D'Amico AV, Spratt DE, Yu JB, Nguyen PL, Rebbeck TR, Mahal BA. Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer. 2019 10 01; 125(19):3338-3346. PMID: 31251398.
    Citations:    
  19. Butler SS, Mahal BA, Lamba N, Mossanen M, Martin NE, Mouw KW, Nguyen PL, Muralidhar V. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. Cancer. 2019 09 15; 125(18):3164-3171. PMID: 31150125.
    Citations:    
  20. Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, Spratt DE, Trinh QD, Nguyen PL, Rebbeck TR, Mahal BA. Active Surveillance for Low-Risk Prostate Cancer in Black Patients. N Engl J Med. 2019 05 23; 380(21):2070-2072. PMID: 31116925.
    Citations:    
  21. King MT, Yang DD, Muralidhar V, Mahal B, Butler S, Devlin PM, Lee LJ, Mouw KW, Martin NM, D'Amico AV, Nguyen PL, Orio PF. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy. 2019 Mar - Apr; 18(2):186-191. PMID: 30638912.
    Citations:    Fields:    
  22. King MT, Nguyen PL, Boldbaatar N, Yang DD, Muralidhar V, Tempany CM, Cormack RA, Hurwitz MD, Suh WW, Pomerantz MM, D'Amico AV, Orio PF. Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. Brachytherapy. 2019 Mar - Apr; 18(2):198-203. PMID: 30638910.
    Citations:    Fields:    
  23. Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Eur Urol. 2019 01; 75(1):35-41. PMID: 30554605.
    Citations:    
  24. Muralidhar V, Nipp RD, Mamon HJ, Punglia RS, Hong TS, Ferrone C, Fernandez-Del Castillo C, Parikh A, Nguyen PL, Wo JY. Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. Ann Surg Oncol. 2018 Dec; 25(13):4027-4034. PMID: 30298331.
    Citations:    Fields:    
  25. Yang DD, Muralidhar V, Mahal BA, Beard CJ, Mouw KW, Martin NE, Orio PF, King MT, Nguyen PL. Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol. 2018 10; 41(10):953-959. PMID: 29045266.
    Citations:    Fields:    
  26. Dinh KT, Aizer AA, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. Am J Med. 2018 05; 131(5):517-523. PMID: 29555248.
    Citations:    Fields:    
  27. Vastola ME, Yang DD, Muralidhar V, Mahal BA, Lathan CS, McGregor BA, Nguyen PL. Laboratory Eligibility Criteria as Potential Barriers to Participation by Black Men in Prostate Cancer Clinical Trials. JAMA Oncol. 2018 Mar 01; 4(3):413-414. PMID: 29423505.
    Citations:    Fields:    
  28. King MT, Chen MH, Moran BJ, Braccioforte MH, Buzurovic I, Muralidhar V, Yang DD, Mouw KW, Devlin PM, D'Amico AV, Nguyen PL, Orio PF. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urol Oncol. 2018 04; 36(4):157.e15-157.e20. PMID: 29276060.
    Citations:    Fields:    Translation:Humans
  29. Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng FY, Hoffman KE, Martin NE, Spratt DE, Yu JB, Orio PF, Nguyen PL. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer. 2018 03 15; 124(6):1141-1149. PMID: 29231964.
    Citations: 1     Fields:    
  30. Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. Clin Genitourin Cancer. 2018 06; 16(3):226-234. PMID: 29196209.
    Citations:    Fields:    
  31. Yang DD, Muralidhar V, Mahal BA, Nguyen PL, Devlin PM, King MT, Orio PF. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. Int J Radiat Oncol Biol Phys. 2018 01 01; 100(1):53-58. PMID: 29254781.
    Citations: 1     Fields:    Translation:Humans
  32. Yang DD, Mahal BA, Muralidhar V, Boldbaatar N, Labe SA, Nezolosky MD, Vastola ME, Beard CJ, Martin NE, Mouw KW, Orio PF, King MT, Nguyen PL. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Cancer. 2017 Dec 15; 123(24):4832-4840. PMID: 28832984.
    Citations:    Fields:    Translation:Humans
  33. Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF, King MT. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):904-911. PMID: 29063853.
    Citations: 1     Fields:    Translation:Humans
  34. Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. Eur Urol Focus. 2019 01; 5(1):69-76. PMID: 28753811.
    Citations: 1     Fields:    
  35. Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urol Oncol. 2017 09; 35(9):542.e25-542.e32. PMID: 28533151.
    Citations:    Fields:    Translation:Humans
  36. Sinha S, Muralidhar V, Feng FY, Nguyen PL. Characteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer. Prostate Int. 2017 Sep; 5(3):89-94. PMID: 28828351.
    Citations:    
  37. Yang DD, Muralidhar V, Mahal BA, Labe SA, Nezolosky MD, Vastola ME, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Spratt DE, Hoffman KE, Feng FY, Nguyen PL. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):338-343. PMID: 28463152.
    Citations:    Fields:    Translation:Humans
  38. Kamran SC, Harshman LC, Bhagwat MS, Muralidhar V, Nguyen PL, Martin NE, La Follette S, Faso S, Viswanathan AN, Efstathiou JA, Beard CJ. Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. Adv Radiat Oncol. 2017 Apr-Jun; 2(2):140-147. PMID: 28740925.
    Citations:    
  39. Bernard B, Muralidhar V, Chen YH, Sridhar SS, Mitchell EP, Pettaway CA, Carducci MA, Nguyen PL, Sweeney CJ. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer. 2017 05 01; 123(9):1536-1544. PMID: 28055108.
    Citations:    Fields:    Translation:Humans
  40. Muralidhar V, Mahal BA, Rose BS, Chen YW, Nezolosky MD, Efstathiou JA, Beard CJ, Martin NE, Orio PF, Trinh QD, Choueiri TK, Sweeney CJ, Nguyen PL. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3. PMID: 28462857.
    Citations:    Fields:    Translation:Humans
  41. Sridharan V, Muralidhar V, Margalit DN, Tishler RB, DeCaprio JA, Thakuria M, Rabinowits G, Schoenfeld JD. Merkel Cell Carcinoma: A Population Analysis on Survival. J Natl Compr Canc Netw. 2016 10; 14(10):1247-1257. PMID: 27697979.
    Citations: 1     Fields:    Translation:Humans
  42. Chen YW, Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Choueiri TK, Hoffman KE, Martin NE, Orio PF, Sweeney CJ, Feng FY, Trinh QD, Nguyen PL. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700. PMID: 27528590.
    Citations:    Fields:    Translation:Humans
  43. Muralidhar V, Nguyen PL. Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies. Urol Oncol. 2017 02; 35(2):76-85. PMID: 27473636.
    Citations: 2     Fields:    Translation:Humans
  44. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer. 2016 Nov 15; 122(21):3371-3377. PMID: 27434225.
    Citations:    Fields:    Translation:Humans
  45. Muralidhar V, Nguyen PL, Tucker-Seeley RD. Recent relocation and decreased survival following a cancer diagnosis. Prev Med. 2016 08; 89:245-250. PMID: 27287662.
    Citations:    Fields:    Translation:Humans
  46. Muralidhar V, Rose BS, Chen YW, Nezolosky MD, Nguyen PL. Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice? Int J Radiat Oncol Biol Phys. 2016 10 01; 96(2):313-317. PMID: 27496390.
    Citations: 5     Fields:    Translation:Humans
  47. Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol. 2016 06 01; 34(16):1905-12. PMID: 27069075.
    Citations: 9     Fields:    Translation:Humans
  48. Muralidhar V, Catalano PJ, Reznor G, Mahal BA, Choueiri TK, Sweeney CJ, Martin NE, Beard CJ, Chen YW, Nezolosky MD, Hoffman KE, Feng FY, Trinh QD, Nguyen PL. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw. 2016 04; 14(4):421-8. PMID: 27059190.
    Citations:    Fields:    Translation:Humans
  49. Mahal BA, Chen YW, Efstathiou JA, Muralidhar V, Hoffman KE, Yu JB, Feng FY, Beard CJ, Martin NE, Orio PF, Nguyen PL. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 05 15; 122(10):1505-12. PMID: 26970022.
    Citations: 5     Fields:    Translation:Humans
  50. Muralidhar V, Nipp RD, Ryan DP, Hong TS, Nguyen PL, Wo JY. Association Between Very Small Tumor Size and Increased Cancer-Specific Mortality in Node-Positive Colon Cancer. Dis Colon Rectum. 2016 Mar; 59(3):187-93. PMID: 26855392.
    Citations: 1     Fields:    Translation:Humans
  51. Muralidhar V, Xiang M, Orio PF, Martin NE, Beard CJ, Feng FY, Hoffman KE, Nguyen PL. Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy. 2016 Feb; 8(1):1-6. PMID: 26985191.
    Citations: 5     
  52. Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, Choueiri TK, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305. PMID: 26778006.
    Citations: 1     Fields:    Translation:Humans
  53. Chen YW, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF, Nguyen PL. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):683-90. PMID: 26972640.
    Citations: 8     Fields:    Translation:Humans
  54. Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol. 2015 Dec; 35 Suppl:S276-S304. PMID: 26590477.
    Citations: 25     Fields:    Translation:HumansCells
  55. Nezolosky MD, Dinh KT, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urol Oncol. 2016 Feb; 34(2):57.e15-22. PMID: 26476663.
    Citations: 4     Fields:    Translation:Humans
  56. Hirschey MD, DeBerardinis RJ, Diehl AME, Drew JE, Frezza C, Green MF, Jones LW, Ko YH, Le A, Lea MA, Locasale JW, Longo VD, Lyssiotis CA, McDonnell E, Mehrmohamadi M, Michelotti G, Muralidhar V, Murphy MP, Pedersen PL, Poore B, Raffaghello L, Rathmell JC, Sivanand S, Vander Heiden MG, Wellen KE. Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol. 2015 Dec; 35 Suppl:S129-S150. PMID: 26454069.
    Citations: 43     Fields:    Translation:HumansCells
  57. Dinh KT, Muralidhar V, Mahal BA, Chen YW, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Occult High-risk Disease in Clinically Low-risk Prostate Cancer with =50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? Urology. 2016 Jan; 87:125-32. PMID: 26391387.
    Citations: 1     Fields:    Translation:Humans
  58. Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Feng FY, Martin NE, Efstathiou JA, Choueiri TK, Pomerantz MM, Sweeney CJ, Trinh QD, Vander Heiden MG, Nguyen PL. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85. PMID: 26235660.
    Citations: 1     Fields:    Translation:Humans
  59. Mahal BA, Muralidhar V, Chen YW, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Trinh QD, Nguyen PL. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU Int. 2016 Jul; 118(1):95-101. PMID: 26207642.
    Citations: 3     Fields:    Translation:Humans
  60. Muralidhar V, Mahal BA, Nguyen PL. Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis. Radiat Oncol. 2015 Jul 30; 10:155. PMID: 26220664.
    Citations: 2     Fields:    Translation:Humans
  61. Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):828-35. PMID: 26530751.
    Citations: 7     Fields:    Translation:Humans
  62. Muralidhar V, Ziehr DR, Mahal BA, Chen YW, Nezolosky MD, Viswanathan VB, Choueiri TK, Sweeney CJ, Trinh QD, Nguyen PL. Association Between Older Age and Increasing Gleason Score. Clin Genitourin Cancer. 2015 Dec; 13(6):525-30.e1-3. PMID: 26119229.
    Citations: 2     Fields:    Translation:Humans
  63. Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Risk of prostate cancer mortality in men with a history of prior cancer. BJU Int. 2016 06; 117(6B):E20-8. PMID: 25845283.
    Citations: 1     Fields:    Translation:Humans
  64. Muralidhar V, Dinh KT, Mahal BA, Ziehr DR, Chen YW, Viswanathan VB, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol. 2015 Jul; 33(7):330.e19-25. PMID: 25990612.
    Citations: 3     Fields:    Translation:Humans
  65. Muralidhar V, Mahal BA, Ziehr DR, Chen YW, Nezolosky MD, Viswanathan VB, Beard CJ, Devlin PM, Martin NE, Orio PF, Nguyen PL. Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. Brachytherapy. 2015 Jul-Aug; 14(4):511-6. PMID: 25887342.
    Citations: 1     Fields:    Translation:Humans
  66. Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015 Aug; 194(2):343-9. PMID: 25681290.
    Citations: 21     Fields:    Translation:Humans
  67. Puram SV, Yarlagadda BB, Sethi R, Muralidhar V, Chambers KJ, Emerick KS, Rocco JW, Lin DT, Deschler DG. Transfusion in head and neck free flap patients: practice patterns and a comparative analysis by flap type. Otolaryngol Head Neck Surg. 2015 Mar; 152(3):449-57. PMID: 25628368.
    Citations: 1     Fields:    Translation:Humans
  68. Lunt SY, Muralidhar V, Hosios AM, Israelsen WJ, Gui DY, Newhouse L, Ogrodzinski M, Hecht V, Xu K, Acevedo PN, Hollern DP, Bellinger G, Dayton TL, Christen S, Elia I, Dinh AT, Stephanopoulos G, Manalis SR, Yaffe MB, Andrechek ER, Fendt SM, Vander Heiden MG. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol Cell. 2015 Jan 08; 57(1):95-107. PMID: 25482511.
    Citations: 52     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Muralidhar's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (167)
Explore
_
Co-Authors (73)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.